Categories Uncategorized

ChineseInvestors.com, Inc. (CIIX) Executes a First to Market Milestone

A population of over 1.2 billion people is one heck of a target market, especially when insulated by language. ChineseInvestors.com (OTCQB: CIIX) has leveraged this demographic to market a broad range of products, services and information specifically for the Chinese speaking population. The company provides real-time market commentary, analysis, and education-related services in the Chinese language and offers several types of subscription-based services. Headquartered in Los Angeles with offices in New York City and Shanghai, the company also offers consultation services to private companies seeking to go public, as well as advertising and public relations services.

Seizing opportunity, this diverse multi-faceted company recently executed a first-to-market milestone by creating the world’s only Chinese language, cannabinoid-based therapeutic health products online store, www.ChineseCBDoil.com. To supply consistently high quality products, the company entered into a wholesale agreement with a well-known CBD oil health brand manufacturer in January.

Marijuana use in China is illegal, but there are no legal strictures on the sale or use of therapeutic cannabis-based oils. Cannabidiol (CBD) oil is considered to have a broad range of medical benefits and, unlike medical marijuana products, CBD oil is non-psychoactive with low THC and high CBD content. CBD has shown varying efficacy in treating epilepsy, Alzheimer’s disease and cirrhosis, as well as providing relief from anxiety and stress. CBD interacts with the body through the endocannabinoid system. The endocannabinoid system regulates the body’s homeostasis, or general state of balance, impacting such functions as mood, sleep, appetite, hormone regulation, pain and immune response. Even more benefits are expected to be uncovered upon completion of ongoing research.

Given the wide-ranging practice of holistic-based Eastern medicine, acceptance and use of CBD oils is not only a natural adjunct but also an enormous potential revenue generator for ChineseInvestors.com.

For more information, visit the company’s website at www.ChineseInvestors.com

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.

Please see full disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/

PsychedelicNewsWire (PNW)
San Francisco, CO
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies

The company has refiled its Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free IV…

3 weeks ago

Global Psychedelic Week 2025 to Unite 5,000 People Across 100 Countries

The world’s first distributed psychedelic conference debuts with a global hybrid experience, 100+ speakers, 60+…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition

FDA grants NRx Pharmaceuticals approval of a Suitability Petition for single-patient preservative-free ketamine. The decision…

4 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression

The FDA designation expands the drug’s potential patient pool tenfold, to an estimated 13 million…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative

NRx Pharmaceuticals has filed a Citizen Petition with the FDA to remove benzethonium chloride from…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

4 months ago